1. E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas
- Author
-
Lepu Zhou, Walter Birchmeier, and K. Schwechheimer
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Malignant meningioma ,Blotting, Western ,Biology ,Pathology and Forensic Medicine ,Meningioma ,Meningeal Neoplasms ,otorhinolaryngologic diseases ,medicine ,Humans ,Meningeal Neoplasm ,neoplasms ,Molecular Biology ,Aged ,Retrospective Studies ,Medulloblastoma ,Pineoblastoma ,Immunochemistry ,Antibodies, Monoclonal ,Astrocytoma ,Glioma ,Cell Biology ,General Medicine ,Middle Aged ,Cadherins ,medicine.disease ,Immunohistochemistry ,Choroid plexus papilloma ,nervous system diseases ,Female ,Oligodendroglioma ,Neoplasm Recurrence, Local - Abstract
Cadherins are a family of glycoproteins that are associated with cell adhesion mechanisms. They are divided into subclasses. The E- and P-cadherins are regarded as the epithelial subtype. Their expression has been demonstrated in many different carcinoma types. Using immunomorphological techniques, we studied the expression of E-cadherin in a series of 145 human brain tumours with the monoclonal antibody 5H9. Western blot analysis was used to confirm the immunohistochemical data. The tumour types represented were astrocytoma WHO I (n = 7), astrocytoma WHO II (n = 6), astrocytoma WHO III (n = 14), glioblastoma WHO IV (n = 8), oligodendroglioma WHO II (n = 5), ependymoma WHO II (n = 5), choroid plexus papilloma WHO I (n = 5), pineoblastoma WHO IV (n = 5), medulloblastoma WHO IV (n = 5), neurinoma WHO I (n = 5), meningioma WHO I and WHO III (n = 75) and pituitary adenoma WHO I (n = 5). Only choroid plexus papillomas (5/5) and meningiomas showed E-cadherin expression. In benign meningiomas (n = 45; 100%), positive E-cadherin immunoreactivity was found regardless of the histomorphological subtype. E-Cadherin was also expressed in 21 WHO I meningiomas (100%) invading dura, bone, brain, and muscle. In contrast, E-cadherin was absent from the majority of morphologically malignant meningiomas (6/9, 66.6%). In addition, in recurrent meningiomas (n = 9), E-cadherin expression in the recurrent tumours was identical to that in the primary neoplasm except in cases with malignant progression, where the malignant recurrent tumour was E-cadherin negative. In 2 cases of metastasizing meningiomas, no E-cadherin immunoreactivity was found in the primary tumours or their metastases.
- Published
- 1998